PYXIS INNOVATIONS INC 4

4 · INTERLEUKIN GENETICS INC · Filed May 21, 2013

Form 4

Period: 2013-05-17

10% Owner

Transactions

Conversion
Common Stock
2013-05-17$5.68/sh+2,521,222$14,316,255→ 37,565,478 total
Conversion
Common Stock
2013-05-17+28,160,200→ 35,044,256 total
Conversion
Convertible Promissory Notes
2013-05-17−14,316,255→ 0 total
Exercise: $5.68→ Common Stock (2,521,222 underlying)
Conversion
Series A-1 Preferred Stock
2013-05-17−5,000,000→ 0 total
→ Common Stock (28,160,200 underlying)

Footnotes (2)

[F1]On May 17, 2013, Pyxis Innovations Inc. ("Pyxis") converted 5,000,000 shares of the Issuer's Series A-1 preferred stock into 28,160,200 shares of common stock. The Series A-1 was convertible into an aggregate of 28,160,200 shares of the Issuer's common stock (equal to $9 million divided by $0.3196, under the terms of the Series A-1 Preferred Stock). Such conversion right did not expire.
[F2]On May 17, 2013, Pyxis converted seven convertible promissory notes in the aggregate principal amount of $14,316,255 issued by the Issuer at a conversion price of $5.6783 per share, resulting in the acquisition by Pyxis of 2,521,222 shares of the Issuer's common stock. The notes were convertible at any time before the payment in full of notes, which had a maturity date of March 31, 2014.

Documents

1 file